Literature DB >> 27210814

CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease.

Rodrigo Liberal1, Charlotte R Grant2, Yun Ma2, Eva Csizmadia3, Zhenghui Gordon Jiang3, Michael A Heneghan2, Eric U Yee4, Giorgina Mieli-Vergani5, Diego Vergani2, Simon C Robson3, Maria Serena Longhi6.   

Abstract

BACKGROUND & AIMS: T-helper-type 17 (Th17) cells are involved in autoimmune tissue damage. CD39 is an ectonucleotidase that catalyzes extracellular ATP/ADP hydrolysis, culminating in the generation of immunosuppressive adenosine. Functional CD39 expression confers immunosuppressive properties upon immune cells. As the proportion of CD39 lymphocytes is decreased in juvenile autoimmune liver disease (AILD), we have explored whether decreased CD39 expression is present on Th17 cells and whether this phenomenon is associated with heightened effector function and inflammation.
METHODS: Thirty-eight patients with juvenile AILD (22 autoimmune hepatitis and 16 autoimmune sclerosing cholangitis), 8 disease controls (DC) and 16 healthy subjects (HS) were studied. Peripheral blood cell phenotype was determined by flow cytometry; ability to suppress by inhibition of cell proliferation/effector cytokine production; ectoenzymatic activity by thin layer chromatography; expression of adenosine receptor, adenosine deaminase (ADA) and phosphodiesterases (PDE) by quantitative real-time PCR or by Western Blot.
RESULTS: CD39(+) Th17 (Th17(CD39+)) cells from HS appear activated and contain high frequencies of lymphocytes producing regulatory cytokines. In AILD, however, Th17(CD39+) cells are markedly diminished and fail to generate AMP/adenosine, thereby limiting control of both target cell proliferation and IL-17 production. When compared to HS, Th17 cells from AILD patients also show lower A2A adenosine receptor expression while displaying similar levels of PDE4A, PDE4B and ADA. Only rare Th17(CD39+) cells are observed by liver immunohistochemistry.
CONCLUSIONS: Th17(CD39+) cells in juvenile AILD are both quantitatively decreased and qualitatively deficient. Low levels CD39 and A2A expression may contribute to the perpetuation of Th17 cell effector properties and unfettered inflammation in this disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ATP; Adenosine; Autoimmune liver disease; CD39; Th17 cells

Mesh:

Substances:

Year:  2016        PMID: 27210814      PMCID: PMC6348153          DOI: 10.1016/j.jaut.2016.05.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  26 in total

1.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

2.  Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.

Authors:  Maria Serena Longhi; Munther J Hussain; Ragai R Mitry; Sunil K Arora; Giorgina Mieli-Vergani; Diego Vergani; Yun Ma
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

3.  STAT3 regulates cytokine-mediated generation of inflammatory helper T cells.

Authors:  Xuexian O Yang; Athanasia D Panopoulos; Roza Nurieva; Seon Hee Chang; Demin Wang; Stephanie S Watowich; Chen Dong
Journal:  J Biol Chem       Date:  2007-02-03       Impact factor: 5.157

4.  ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors.

Authors:  Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger
Journal:  Science       Date:  2006-12-15       Impact factor: 47.728

5.  Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.

Authors:  G V Gregorio; B Portmann; J Karani; P Harrison; P T Donaldson; D Vergani; G Mieli-Vergani
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

6.  Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort).

Authors:  Bruce W Kirkham; Marissa N Lassere; John P Edmonds; Katherine M Juhasz; Paul A Bird; C Soon Lee; Ron Shnier; Ian J Portek
Journal:  Arthritis Rheum       Date:  2006-04

7.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis.

Authors:  D Matusevicius; P Kivisäkk; B He; N Kostulas; V Ozenci; S Fredrikson; H Link
Journal:  Mult Scler       Date:  1999-04       Impact factor: 6.312

8.  Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

Authors:  Maria Serena Longhi; Yun Ma; Dimitrios P Bogdanos; Paul Cheeseman; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Hepatol       Date:  2004-07       Impact factor: 25.083

9.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

Authors:  Gerald G Krueger; Richard G Langley; Craig Leonardi; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Lisa T Dooley; Mark Lebwohl
Journal:  N Engl J Med       Date:  2007-02-08       Impact factor: 91.245

10.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Authors:  Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more
  15 in total

1.  HIF-1α-induced xenobiotic transporters promote Th17 responses in Crohn's disease.

Authors:  Anyan Xie; René J Robles; Samiran Mukherjee; Haohai Zhang; Linda Feldbrügge; Eva Csizmadia; Yan Wu; Keiichi Enjyoji; Alan C Moss; Leo E Otterbein; Francisco J Quintana; Simon C Robson; Maria Serena Longhi
Journal:  J Autoimmun       Date:  2018-08-08       Impact factor: 7.094

Review 2.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 3.  Th17 cells in the liver: balancing autoimmunity and pathogen defense.

Authors:  Nobuhito Taniki; Nobuhiro Nakamoto; Po-Sung Chu; Masataka Ichikawa; Toshiaki Teratani; Takanori Kanai
Journal:  Semin Immunopathol       Date:  2022-02-24       Impact factor: 11.759

4.  Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis.

Authors:  C R Grant; B S Holder; R Liberal; M A Heneghan; Y Ma; G Mieli-Vergani; D Vergani; M S Longhi
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

5.  Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.

Authors:  Rodrigo Liberal; Charlotte R Grant; Muhammed Yuksel; Jonathon Graham; Alireza Kalbasi; Yun Ma; Michael A Heneghan; Giorgina Mieli-Vergani; Diego Vergani; Maria Serena Longhi
Journal:  Hepatology       Date:  2017-10-03       Impact factor: 17.425

6.  Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis.

Authors:  Marta Vuerich; Rasika Harshe; Luiza Abrahão Frank; Samiran Mukherjee; Barbora Gromova; Eva Csizmadia; Imad A M Nasser; Yun Ma; Alan Bonder; Vilas Patwardhan; Simon C Robson; Maria Serena Longhi
Journal:  J Hepatol       Date:  2020-07-11       Impact factor: 25.083

Review 7.  Novel Immunotherapies for Autoimmune Hepatitis.

Authors:  Shamir Cassim; Marc Bilodeau; Catherine Vincent; Pascal Lapierre
Journal:  Front Pediatr       Date:  2017-01-26       Impact factor: 3.418

8.  Clinical significance of changes in the Th17/Treg ratio in autoimmune liver disease.

Authors:  Ting-Ting Feng; Ting Zou; Xin Wang; Wei-Feng Zhao; Ai-Lan Qin
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

9.  IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.

Authors:  Stephanie Stein; Lara Henze; Tobias Poch; Antonella Carambia; Till Krech; Max Preti; Fenja Amrei Schuran; Maria Reich; Verena Keitel; Romina Fiorotto; Mario Strazzabosco; Lutz Fischer; Jun Li; Luisa Marie Müller; Jonas Wagner; Nicola Gagliani; Johannes Herkel; Dorothee Schwinge; Christoph Schramm
Journal:  J Hepatol       Date:  2020-11-13       Impact factor: 25.083

Review 10.  The role of adenosinergic pathway in human autoimmune diseases.

Authors:  Ke Dong; Zhao-Wei Gao; Hui-Zhong Zhang
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.